Compugen (CGEN) Stifel 2024 Healthcare Conference summary

Key clinical data and insights

• Triplet therapy in platinum-resistant ovarian cancer showed a 20% overall response rate and 45% disease control, with durable responses and a favorable safety profile.

• COM701’s mechanism targets PVRIG, working in parallel with TIGIT and PD-1, enhancing T cell infiltration and tumor susceptibility to immunotherapy.

• Monotherapy with COM701 in platinum-sensitive patients is planned, supported by prior disease control and durable partial response in a small cohort.

• Adaptive platform trial will enroll 60 patients (2:1 randomization), with PFS as the primary endpoint and interim analysis in H2 2026.

• Addressable market for third-line platinum-sensitive ovarian cancer estimated at 7,000–10,000 patients globally.

Pipeline and partnership updates

• COM503, an IL-18 pathway antibody, will enter phase 1 trials, aiming to release active IL-18 in tumors by blocking its natural inhibitor.

• Phase 1 for COM503 will test both monotherapy and combination with Gilead’s PD-1 drug, focusing on inflamed tumor types.

• Gilead partnership includes $60M upfront, $30M IND milestone, and eligibility for over $750M in future milestones plus royalties.

• AstraZeneca’s TIGIT/PD-1 bispecific, based on licensed technology, is in five phase 3 trials, with optimism based on phase 2 efficacy and safety data.

• Ongoing investment in computational discovery platform continues to drive pipeline expansion and business development collaborations.

Forward-looking statements and trial execution

• Aggressive enrollment planned for the new COM701 trial, leveraging established investigator networks and a favorable competitive landscape.

• Interim analysis for the COM701 trial will use both event monitoring and a fixed analysis, overseen by an independent data monitoring committee.

• If successful, COM701 could expand into earlier lines of therapy and serve as a backbone for future combination studies.

• Partnerships with Gilead and AstraZeneca provide significant revenue potential and strategic value for pipeline advancement.

• Continued focus on internal pipeline development balanced with external collaborations to ensure sustainability and growth.